Engage Treatment

Non-adherence in chronic patients is an important problem, both because of its high prevalence (various studies show that up to 50% of chronic patients may not be adherent to prescribed treatments) and because of its consequences for patient health (poorer disease control, reduced quality of life and life expectancy), as well as increased healthcare costs10.

10 According to data from the SEFH in Europe, this lack of adherence can cost up to 125,000 million euros and contribute to the premature death of 200,000 people per year. Worldwide there are an estimated 150 million chronic patients and by 2030 this figure is expected to rise to 171 million. Causes of non-adherence

Engage Treatment is a tool in the form of an App designed to improve adherence to treatment. 

We help patients to become aware of their disease and we provide them with an accompanied follow-up to guide them at the beginning and in their daily life in order to organize and understand the disease in a simple and graphic way. 

Our App is intended for all those chronic patients who take a lot of medication and their adherence to treatment is null for their quality of life.

 In the following excerpt from a study ordered by Addenbrooke's Hospital, Cambridge, you can see how poor adherence to treatment can affect their quality of life.

Medication nonadherence represents a modifiable risk factor for patients with hypertension. Identification of nonadherent patients could have significant clinical and economic implications in the management of uncontrolled hypertension.

We analysed the results of 174 urinary adherence screens from patients referred to Addenbrooke's Hospital, Cambridge, for uncontrolled hypertension. Cases were identified for evaluation by results of liquid chromatography-tandem mass spectrometry of urine samples (males: 91; females: 83; age range: 17–87). We performed a binary logistic regression analysis for nonadherence using age, sex, and number of medications prescribed (both antihypertensives and non-antihypertensives separately) as independent predictors. Rates of nonadherence for individual antihypertensive drugs were calculated if prescribed to ≥10 patients.

The overall rate of nonadherence to one or more prescribed antihypertensive medications was 40.3%. 14.4% of all patients were nonadherent to all prescribed antihypertensive medications (complete nonadherence), whereas 25.9% of all patients were nonadherent to at least 1, (but not all) prescribed antihypertensive medications (partial nonadherence). 72% of patients were prescribed ≥3 antihypertensives And for every increase in the number of antihypertensive medications prescribed, nonadherence increased with adjusted odds ratios of 2.9 (P < .001). Logistic regression showed that women were 3.3 times more likely to be nonadherent (P = .004). Polypharmacy (≥6 medications prescribed for hypertension and/or concomitant comorbidities) was prevalent in 52%. Bendroflumethiazide and chlortalidone demonstrated the highest and lowest nonadherences respectively (45.5% and 11.8%).

Rate of nonadherence in patients with hypertension was significantly impacted by sex and number of antihypertensive medications prescribed. Understanding these factors is crucial in identifying and managing nonadherence.

We are the right people to bring this product to the market, because I was on dialysis for 4 years and have been a kidney transplant recipient for 6 years.

I have been actively participating in the association of kidney diseases and we have come to the conclusion of the importance of good adherence to treatment and I have decided with my team to find a solution that is close to the patient and help him in his day to day life.

This application seeks to raise awareness with new technologies for a good follow-up of the prescribed medication and would help many patients with chronic diseases.

The first is financial support in order to make a powerful app for patients with chronic and rare diseases we need support for both product validation and healthcare to test with patients the efficacy of the app.

We believe that this challenge will make us more visible and will help us to bring this idea to the market and to what matters most to us, the patient's wellbeing.

Because we are familiar with the problem and we believe that with a powerful application we can help the patient's wellbeing by using technology so that they can follow their treatment and improve their quality of life every day.

In the next five years our goal is to improve the application and to have achieved that our product has evolved and we have more sanitary applications attending the demand of other diseases.

In number 3 of the UN SDGs where it tells us that guaranteeing a healthy life and promoting well-being at all ages is essential for sustainable development.

We believe that with the data provided of non-adherence to treatment in chronic patients or rare diseases the patient worsens, we believe that with this solution that we propose we can generate well-being both in the patient and in the people who accompany him.

Our theory is that we touch on a topic where the data is very clear and with our solution we can improve the lives of patients.

Non-adherence in chronic patients is an important problem, both because of its high prevalence (various studies show that up to 50% of chronic patients may not be adherent to prescribed treatments) and because of its consequences for patient health (poorer disease control, reduced quality of life and life expectancy), as well as increased healthcare costs10.

10 According to data from the SEFH in Europe, this lack of adherence can cost up to 125,000 million euros and contribute to the premature death of 200,000 people per year. Worldwide there are an estimated 150 million chronic patients and by 2030 this figure is expected to rise to 171 million. Causes of non-adherence

For us, innovation and development are our priorities and we want to include AI in our application.
Since we have seen the great results that the combination of medicine and artificial intelligence is giving.

We are a diverse and multidisciplinary team where respect and commitment are the cornerstone that guides our path.

So it is, our business model in the Canva model, in just nine building blocks, which are
 
Problem:
The user or patient is not willing to pay to use health applications.
 
Solution:
A patient support application that guides you in a simple way in the management of your chronic disease.
 
Unique value proposition:
We help patients to manage their chronic illness more comfortably, insurers to optimize costs per patient and pharmaceutical companies to provide statistical information on the consumption of their product.
 
Benefit of the proposal:
Savings, anticipation and prevention of the mistakes that patients usually make in treatment and scalability.
 
Customer segments:
 Chronic patients, insurance companies, pharmaceutical companies.
 
Key metrics:
         Cost savings - Result of efficiency in treatment adherence.
 
Channels:
B2B with insurance companies and pharmaceutical companies.
 
Cost structure:
         Development and implementation of software and servers.
         Adding the cost for the information.
 
Income routes:
         It would be the statistics that we offer to pharmaceutical companies and the savings that we generate to insurers.

Our financing model is to make our solution attractive to pharmaceutical companies so that they invest in its development and its subsequent benefit.

So far we have worked on the application as a concept of an idea, waiting for funding to make a prototype and verify it to have a product certified in quality and well-being for the end user.